Document is current
Any future updates will be listed below
-
Authors
Abegglen, Lisa M. https://orcid.org/0000-0003-3607-3001
Rogers, Aaron
Mitchell, Gareth
Bradley Nelson, C.
Sanborn, Madison I.
Kennington, Ryan https://orcid.org/0009-0001-8888-268X
Rogers, McKenna
Pearson, Virginia R. https://orcid.org/0000-0002-1903-613X
Sharp, Miranda
Howard, Lauren L.
Latimer, Erin
Landolfi, Jennifer A.
Molter, Christine
Crook, Erika
Kiso, Wendy
Schmitt, Dennis https://orcid.org/0000-0003-0023-5427
Ling, Paul D.
Martinod, Kimberly https://orcid.org/0000-0002-1026-6107
Schiffman, Joshua D. https://orcid.org/0000-0002-6968-7694
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217376)
University of Utah | Department of Pediatrics Research Enterprise
- License Information
-
More Information
Article History
Received: 29 September 2025
Accepted: 14 May 2026
First Online: 30 May 2026
Competing interests
: The authors declare the following competing interests: J.D.S. is co-founder, shareholder, and employed by Peel Therapeutics, Inc., a company developing evolution-inspired medicines based on cancer resistance in elephants. L.M.A. is a shareholder and consultant to Peel Therapeutics, Inc. The other authors declare no competing interests.
